PHARMAC is seeking feedback on a proposal to list rehabilitation equipment, patient positioning products and supports supplied by Medix 21 Limited in Part III of Section H of the Pharmaceutical Schedule from 1 September 2020.
Closes: 4pm Thurday 23 July 2020.
PHARMAC is pleased to announce a decision to list mifepristone in Section B of the Pharmaceutical Schedule, enabling it to be supplied on a Practitioners’ Supply Order (PSO); and amend the listing of misoprostol in Section B of the Pharmaceutical Schedule, enabling it to be supplied on a Practitioners’ Supply Order (PSO).
The number of patients who were dispensed cilazapril with hydrochlorothiazide and other commonly used anti-hypertensives.
All communications and reports regarding supply chain issues caused by COVID-19
Request for information about the discontinuation of phenelzine sulphate.
Request for information and statistics on anti-rejection drugs.
Request for information on the number of people prescribed Utrogestan SA and the cost of this.
Why did the number of declined exceptional circumstances applications for lamotrigine decrease between 5 December 2019 and 18 December 2019?
Request for information about the lamotrigine brand change.
Request for information about DHB reporting about and claiming of rebates for special foods.
Request for information about the pharmaceutical Tafamidis and its use in the control of amyloidosis.
Information about PHARMAC funding high-cost medicines.
PHARMAC has resolved to award tenders for Sole Subsidised Supply Status and Hospital Supply Status for some products included in the 2019/20 Invitation to Tender, dated 1 November 2019.
NPPA Applications for the last 5 years and the lamotrigine exceptional circumstances applications
What medicines/ingredients are more expensive (as a result of COVID-19) and by how much have they increased?
The number of complaints received by PHARMAC about funding.
Nationwide Special Authority initiations and renewals by (immunology) indication for adalimumab, etanercept, secukinumab, infliximab, tocilizumab and rituximab, by month from October 2019 to April 2020.
Funding of methylphenidate or similar stimulant medications, for Attention Deficit Hyperactivity Disorder (ADHD).
Special Authority data on pembrolizumab and nivolumab, from Jan 2020 to May 2020.
We are pleased to announce a decision to award sole supply of infliximab, a biologic medicine used to treat a range of inflammatory and autoimmune conditions, from 1 September 2020.